Last reviewed · How we verify
Levothyroxine-Na + iodide
Levothyroxine-Na replaces deficient thyroid hormone to restore normal metabolic function, while iodide provides substrate for thyroid hormone synthesis.
Levothyroxine-Na replaces deficient thyroid hormone to restore normal metabolic function, while iodide provides substrate for thyroid hormone synthesis. Used for Hypothyroidism, Iodine deficiency with hypothyroidism.
At a glance
| Generic name | Levothyroxine-Na + iodide |
|---|---|
| Sponsor | Sanofi |
| Drug class | Thyroid hormone replacement therapy |
| Target | Thyroid hormone receptors (TR-alpha and TR-beta) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Levothyroxine sodium is a synthetic T4 (thyroxine) that is converted peripherally to the active T3 form, restoring thyroid hormone levels in hypothyroidism. The addition of iodide ensures adequate iodine availability for endogenous thyroid hormone production, addressing both hormone replacement and iodine deficiency simultaneously.
Approved indications
- Hypothyroidism
- Iodine deficiency with hypothyroidism
Common side effects
- Tremor
- Tachycardia
- Palpitations
- Anxiety
- Insomnia
- Heat intolerance
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Levothyroxine-Na + iodide CI brief — competitive landscape report
- Levothyroxine-Na + iodide updates RSS · CI watch RSS
- Sanofi portfolio CI